CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
AccuraSee IOPCL with +3.0D adddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05113979
NCT05113979N/ACompleted
CompareCT.gov

Early Feasibility Study to Evaluate the Safety and Effectiveness of the AccuraSee for Secondary Implantation in the Capsular Bag to Correct Residual Refractive Errors of Previous Cataract Surgery

OnPoint Vision Inc·interventional·Posted Nov 9, 2021·Updated Apr 25, 2024

In Brief

A clinical study evaluating AccuraSee IOPCL with +3.0D add for Refractive Errors. Completed, enrolled 10 participants across 1 site.

Detailed Summary

To determine if the intraocular pseudophakic contact lens (IOPCL), referred to as the AccuraSee, corrects residual refractive errors after cataract surgery using a plus powered lens in subjects with ocular pathology previously implanted with a Bausch and Lomb LI61AO or LI61SE monofocal posterior chamber intraocular lens (PCIOL) and to confirm its positional stability and adherence relative to the PCIOL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractive Errors
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 9, 2021
Enrollment StartMar 9, 2020
Primary CompletionSep 9, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.6 years ago

Interventions

AccuraSee IOPCL with +3.0D adddevice

The IOPCL (intraocular pseudophakic contact lens) consists of a 4.5mm diameter optic. All subjects will receive a +3.0 power regardless of diopter power based on IOL Master. This IOPCL will be coupled to a Bausch and Lomb Model LI61SE or LI61AO intraocular lens to correct residual refractive errors after cataract surgery.